Duodenal levodopa infusion for the treatment of Parkinson’s disease

Bibliography

• KOLLER W, WATTS R: Movement Disorders: Neurological Principles and Practice. McGraw Hill (1997) 137-152.
   Google Scholar
• RASCOL O, GOETZ C, KOLLER W, POEWE W, SAMPAIO C: Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet (2002) 359:1589-1598.
   PubMed Web of Science ®Google Scholar
• RAJPUT AH: Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Related Dis. (2001) 8:95-100.
   PubMed Web of Science ®Google Scholar
• NUTT JG, HOLFORD NHG: The response to levodopa in Parkinson’s disease: imposing pharmacological law and order. Ann. Neurol. (1996) 39:561-573.
   PubMed Web of Science ®Google Scholar
• OBESO JA, RODRIGUEZ-OROZ M, MARIN C et al.: The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology (2004) 62: S17-S30.
   PubMed Web of Science ®Google Scholar
• CHAPUIS S, OUCHCHANE L, METZ O, GERBAUD L, DURIF F: Impact of the motor complications of Parkinson's disease on the quality of life. Mov. Disord. (2005) 20:224-230.
   PubMed Web of Science ®Google Scholar
• JENNER P: Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology (2004) 62(1 Suppl. 1):S47-S55.
   PubMed Web of Science ®Google Scholar
• CEDARBAUM JM, KUTT H, MCDOWELL FH: A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology (1989) 39(11 Suppl. 2):38-44.
   PubMedGoogle Scholar
• MANNISTO PT, KAAKKOLA S: Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. (1999) 51(4):593-628.
   PubMed Web of Science ®Google Scholar
• KOLLER WC, HUTTON JT, TOLOSA E, CAPILLDEO R: Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology (1999) 53(5):1012-1019.
   PubMed Web of Science ®Google Scholar
• JENNER P, AL-BARGHOUTHY G, SMITH L et al.: Initiation of entacapone with L-DOPA further improves antiparkinsonian activity and avoids dyskinesia in the MPTP primate model of Parkinson’s disease. Neurology (2002) 58(Suppl. 3):A374-A375.
   Google Scholar
• SMITH LA, JACKSON MJ, AL-BARGHOUTHY G, ROSE S, KUOPPAMAKI M, OLANOW W, JENNER P: Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug naïve primates. Mov. Dis. (2005) 3:306-314.
   Google Scholar
• RASCOL O, BROOKS DJ, KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. (2000) 342:1484-1491.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA (2000) 284:1931-1938.
   PubMedGoogle Scholar
• RASCOL O, BROOKS DJ, KORCZYN AD et al.; 056 STUDY GROUP: Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov. Disord. (2006) 21(11):1844-1850.
   PubMed Web of Science ®Google Scholar
• KURLAN R, NUTT JG, W OODWARD WR et al.: Duodenal and gastric delivery of levodopa in parkinsonism. Ann. Neurol. (1988) 23(6):589-595.
   PubMed Web of Science ®Google Scholar
• KURLAN R, ROTHFIELD KP, WOODWARD WR et al.: Erratic gastric emptying of levodopa may cause ‘random’ fluctuations of parkinsonian mobility. Neurology (1988) 38(3):419-421.
   PubMed Web of Science ®Google Scholar
• NUTT JG, WOODWARD WR, HAMMERSTAD JP, CARTER JH, ANDERSON JL: The ‘on-off’ phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N. Engl. J. Med. (1984) 310(8):483-488.
   PubMed Web of Science ®Google Scholar
• KURLAN R, RUBIN AJ, MILLER C, RIVERA-CALIMLIM L, CLARKE A, SHOULSON I: Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol. (1986) 20(2):262-265.
   PubMed Web of Science ®Google Scholar
• MARICLE RA, NUTT JG, VALENTINE RJ, CARTER JH: Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology (1995) 45(9):1757-1760.
   PubMed Web of Science ®Google Scholar
• LEWITT PA: Levodopa therapeutics: new treatment strategies. Neurology (1993) 43(12 Suppl. 6):S31-S37.
   PubMedGoogle Scholar
• RIVERA-CALIMLIM L, DUJOVNE CA, MORGAN JP, LASAGNA L, BIANCHINE JR: Absorption and metabolism of L-dopa by the human stomach. Eur. J. Clin. Invest. (1971) 1(5):313-320.
   PubMed Web of Science ®Google Scholar
• RIVERA-CALIMLIM L, DUJOVNE CA, MORGAN JP, LASAGNA L, BIANCHINE JR: L-dopa treatment failure: explanation and correction. Br. Med. J. (1970) 4(5727):93-94.
   PubMedGoogle Scholar
• QUIN N, PARKES JD, MARSDEN CD: Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology (1984) 34(9):1131-1136.
   PubMedGoogle Scholar
• KURLAN R, NUTT JG, WOODWARD WR et al.: Duodenal and gastric delivery of levodopa in parkinsonism. Ann. Neurol. (1988) 23(6):589-595.
   PubMed Web of Science ®Google Scholar
• SHOULSON I, GLAUBIGER GA, CHASE TN: On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology (1975) 25(12):1144-1148.
   PubMed Web of Science ®Google Scholar
• HARDIE RJ, MALCOLM SL, LEES AJ, STERN GM, ALLEN JG: The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br. J. Clin. Pharmacol. (1986) 22(4):429-436.
   PubMed Web of Science ®Google Scholar
• DELEU D, EBINGER G, MICHOTTE Y: Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa. Eur. J. Clin. Pharmacol. (1991) 41(5):453-458.
   PubMedGoogle Scholar
• NYHOLM D, ASKMARK H, GOMES-TROLIN C et al.: Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin. Neuropharmacol. (2003) 26(3):156-163.
   PubMed Web of Science ®Google Scholar
• SCHUH LA, BENNETT JP Jr: Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology (1993) 43(8):1545-1550.
   PubMedGoogle Scholar
• STOCCHI F, VACCA L, RUGGIERI S, OLANOW CW: Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol. (2005) 62(6):905-910.
   PubMed Web of Science ®Google Scholar
• KURTH MC, TETRUD JW, TANNER CM et al.: Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology (1993) 43(9):1698-1703.
   PubMed Web of Science ®Google Scholar
• SAGE JI, TROOSKIN S, SONSALLA PK, HEIKKILA R, DUVOISIN RC: Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann. Neurol. (1988) 24(1):87-89.
   PubMed Web of Science ®Google Scholar
• SAGE JI, SCHUH L, HEIKKILA RE, DUVOISIN RC: Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. Clin. Neuropharmacol. (1988) 11(1):36-44.
   PubMed Web of Science ®Google Scholar
• SAGE JI, MCHALE DM, SONSALLA P, VITAGLIANO D, HEIKKILA RE: Continuous levodopa infusions to treat complex dystonia in Parkinson's disease. Neurology (1989) 39(7):888-891.
   PubMed Web of Science ®Google Scholar
• FRANKEL JP, KEMPSTER PA, BOVINGDON M, WEBSTER R, LEES AJ, STERN GM: The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J. Neurol. Neurosurg. Psychiatry. (1989) 52(9):1063-1067.
   PubMed Web of Science ®Google Scholar
• SAGE JI, TROOSKIN S, SONSALLA PK, HEIKKILA RE: Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson's disease. Neurology (1989) 39(11 Suppl. 2):60-63; discussion 72-73.
   PubMedGoogle Scholar
• SAGE JI, SONSALLA PK, MCHALE DM, HEIKKILA RE, DUVOISIN RC: Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson's disease. Adv. Neurol. (1990) 53:383-386.
   PubMedGoogle Scholar
• CEDARBAUM JM, SILVESTRI M, KUTT H: Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology (1990) 40(6):995-997.
   PubMed Web of Science ®Google Scholar
• SAGE JI, MARK MH: Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations. Ann. Neurol. (1991) 30(4):616-617.
   PubMed Web of Science ®Google Scholar
• SYED N, MURPHY J, ZIMMERMAN T Jr, MARK MH, SAGE JI: Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov. Disord. (1998) 13(2):336-338.
   PubMed Web of Science ®Google Scholar
• BREDBERG E, NILSSON D, JOHANSSON K et al.: Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur. J. Clin. Pharmacol. (1993) 45(2):117-122.
   PubMed Web of Science ®Google Scholar
• NILSSON D, HANSSON LE, JOHANSSON K, NYSTROM C, PAALZOW L, AQUILONIUS SM: Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol. Scand. (1998) 97(3):175-183.
   PubMed Web of Science ®Google Scholar
• NILSSON D, NYHOLM D, AQUILONIUS SM: Duodenal levodopa infusion in Parkinson's disease – long-term experience. Acta Neurol. Scand. (2001) 104(6):343-348.
   PubMedGoogle Scholar
• NYHOLM D, NILSSON REMAHL AI et al.: Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology (2005) 64(2):216-223.
   PubMed Web of Science ®Google Scholar
• LUNDQVIST C, NYSTEDT T, REIERTSEN O, GROTLI R, BEISKE AG: Continuous treatment with levodopa of Parkinson disease. Tidsskr Nor Laegeforen. (2005) 125(19):2638-2640.
   PubMedGoogle Scholar
• NYHOLM D, JANSSON R, WILLOWS T, REMAHL IN: Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology (2005) 65(9):1506-1507.
   PubMed Web of Science ®Google Scholar
• JOHNELS B, INGVARSSON PE, THORSELIUS M, VALLS M, STEG G: Disability profiles and objective quantitative assessment in Parkinson's disease. Acta Neurol. Scand. (1989) 79(3):227-238.
   PubMedGoogle Scholar
• NYHOLM D, LEWANDER T, JOHANSSON A, LEWITT PA, LUNDQVIST C, AQUILONIUS SM: Intraduodenal infusion of a gel suspension of levodopa/carbidopa, Duodopa, in advanced Parkinson’s disease: safety, tolerability, efficacy and dosage. Mov. Disord. (2004) 19:S177.
   Google Scholar
• KLEINER-FIS MAN G, SAINT-CYR JA, MIYASAKI J, LOZANO A, LANG AE: Subthalamic DBS replaces levodopa in Parkinson's disease. Neurology (2002) 59(8):1293-1294.
   Google Scholar
• VOON V, KUBU C, KRACK P, HOUETO JL, TROSTER AI: Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov. Disord. (2006) 21(Suppl. 14):S305-S327.
   PubMed Web of Science ®Google Scholar
• WESTIN J, NYHOLM D, GROTH T, DOUGHERTY MS, YERRAMSETTY PK, PALHAGEN SE: Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease. Parkinsonism Relat. Disord. (2006) 12(8):509-513.
   PubMed Web of Science ®Google Scholar
• NUTT JG, CARTER JH, LEA ES, WOODWARD WR: Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov. Disord. (1997) 12(3):285-292.
   PubMed Web of Science ®Google Scholar
• FRANKEL JP, KEMPSTER PA, BOVINGDON M, WEBSTER R, LEES AJ, STERN GM: The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J. Neurol. Neurosurg. Psychiatry (1989) 52(9):1063-1067.
   PubMed Web of Science ®Google Scholar
• NYHOLM D, AQUILONIUS SM: Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin. Neuropharmacol. (2004) 27(5):245-256.
   PubMed Web of Science ®Google Scholar